Cargando…

Efficacy of Intra-Articular Injection of Botulinum Toxin Type A (IncobotulinumtoxinA) in Temporomandibular Joint Osteoarthritis: A Three-Arm Controlled Trial in Rats

Temporomandibular disorders (TMD) are complex pathologies responsible for chronic orofacial pain. Intramuscular injection of botulinum toxin A (BoNT/A) has shown effectiveness in knee and shoulder osteoarthritis, as well as in some TMDs such as masticatory myofascial pain, but its use remains contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Béret, Marie, Barry, Florent, Garcia-Fernandez, Maria-Jose, Chijcheapaza-Flores, Henry, Blanchemain, Nicolas, Chai, Feng, Nicot, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142654/ https://www.ncbi.nlm.nih.gov/pubmed/37104199 http://dx.doi.org/10.3390/toxins15040261

Ejemplares similares

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

Comparison of chemical-induced temporomandibular osteoarthritis rat models (monosodium iodoacetate versus collagenase type II) for the study of prolonged drug delivery systems
por: Barry, Florent, et al.
Publicado: (2023)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial
por: Ângelo, David Faustino, et al.
Publicado: (2023)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
por: Jimenez-Shahed, Joohi
Publicado: (2012)

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
por: Prager, Welf, et al.
Publicado: (2013)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
por: de Sanctis Pecora, Carla
Publicado: (2020)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Albanese, Alberto, et al.
Publicado: (2023)

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
por: Ianieri, Giancarlo, et al.
Publicado: (2018)

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
por: Wissel, Jörg, et al.
Publicado: (2017)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Wissel, Jörg, et al.
Publicado: (2021)

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
por: Berweck, Steffen, et al.
Publicado: (2022)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
por: Hosseini, Meghdad, et al.
Publicado: (2023)

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study
por: Comella, Cynthia, et al.
Publicado: (2022)

Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: protocol for a randomised trial (RHIBOT)
por: Gil, Charlotte, et al.
Publicado: (2018)

IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study
por: Pavicic, Tatjana, et al.
Publicado: (2015)

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
por: Kaňovský, Petr, et al.
Publicado: (2021)

IncobotulinumtoxinA Injection for Treating Children with Idiopathic Toe Walking: A Retrospective Efficacy and Safety Study
por: Filippetti, Mirko, et al.
Publicado: (2022)

IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series
por: da Cunha, Ana Lucia Gonzaga, et al.
Publicado: (2023)

Treatment of Vestibulodynia with Submucosal Injections of IncobotulinumtoxinA into Targeted Painful Points: An Open-Label Exploratory Study
por: Villa-Muñoz, Paula, et al.
Publicado: (2023)

Intra-Articular Injection of Botulinum Toxin for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials
por: Sconza, Cristiano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f7c8o290he37bhrh6jnt5rlb6g